Drug intelligence / Profile preview

GC5125A

Development stage: Preclinical
Lead developer: GC Biopharma
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GC5125A is a recombinant von Willebrand factor (rVWF) replacement therapy being developed by GC Biopharma (formerly Green Cross) for the treatment of von Willebrand disease (vWD). vWD is a hereditary bleeding disorder characterized by a deficiency or defect in von Willebrand factor, a multimeric glycoprotein essential for platelet adhesion to the subendothelium and for the stabilization of coagulation Factor VIII. GC5125A aims to restore these critical hemostatic functions by providing exogenous VWF, thereby controlling or preventing bleeding episodes in affected individuals. The candidate is currently in the preclinical stage of development.

Other names: von Willebrand factor (Green Cross)recombinant von Willebrand factor

Targets

BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on GC5125A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC5125A.

Explore the full profile